about
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of CancerCollagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions.Excretion/secretion products from Schistosoma mansoni adults, eggs and schistosomula have unique peptidase specificity profiles.ADAM Proteases and Gastrointestinal Function.A novel peptide ADAM8 inhibitor attenuates bronchial hyperresponsiveness and Th2 cytokine mediated inflammation of murine asthmatic models.The ADAMs family of proteases as targets for the treatment of cancer.Clinical implications of compounds designed to inhibit ECM-modifying metalloproteinases.Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating MicrovesiclesFine Tuning Cell Migration by a Disintegrin and Metalloproteinases.Expression of the zinc importer protein ZIP9/SLC39A9 in glioblastoma cells affects phosphorylation states of p53 and GSK-3β and causes increased cell migration.YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells.Phagocyte-extracellular matrix crosstalk empowers tumor development and dissemination.ADAM8 expression in breast cancer derived brain metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.Simultaneous Detection of Metalloprotease Activities in Complex Biological Samples Using the PrAMA (Proteolytic Activity Matrix Assay) Method.ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.Considerations on inhibition approaches for proinflammatory functions of ADAM proteases.The metalloproteinase ADAM8 promotes leukocyte recruitment in vitro and in acute lung inflammation.
P2860
Q26774789-81EC8B42-7F02-4A88-8E4B-04327E37EE7EQ33891283-AA29286B-2CE7-46E6-BCFA-77D7EA53F042Q36563765-08D0903C-C1C5-4911-9714-1FABBABEBB81Q37052477-2DE63E32-529B-4C55-9CA9-ECE87316267FQ37125335-E51D80BF-0511-4460-9A05-6F50BB09D216Q37216972-B25419D6-2A64-41C6-AF65-27F31F7E2B76Q38430546-8FD5BB2E-2CDD-425A-A8BD-DBE31F00286DQ38836137-9D7B8F19-B7ED-4631-A54B-E2160F408556Q39162354-57B601B2-62DC-4DB7-8028-D89A91BCDF4FQ39365286-006E10BD-3D05-4B25-BD3A-7120902A80C5Q47405466-EF08F0AD-8046-4D59-B68E-A328940B558EQ47437633-EC7AB493-2D84-4661-8109-493696E8CA04Q47593170-85565DD1-F57C-4A71-B39B-845D1DE22CE4Q47925209-5CBF4095-5A11-47D2-904D-F24F72ED2FAFQ50074642-466EAC71-6B23-4BDE-8E27-8C5514778872Q50495797-F94EB695-A140-4CA6-9D84-CA9332B0E124Q50952999-1BF740A6-4E7F-4045-837E-816B61B6C621
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
ADAM8 as a drug target in pancreatic cancer
@nl
ADAM8 as a drug target in pancreatic cancer.
@ast
ADAM8 as a drug target in pancreatic cancer.
@en
type
label
ADAM8 as a drug target in pancreatic cancer
@nl
ADAM8 as a drug target in pancreatic cancer.
@ast
ADAM8 as a drug target in pancreatic cancer.
@en
prefLabel
ADAM8 as a drug target in pancreatic cancer
@nl
ADAM8 as a drug target in pancreatic cancer.
@ast
ADAM8 as a drug target in pancreatic cancer.
@en
P2093
P2860
P50
P3181
P356
P1476
ADAM8 as a drug target in pancreatic cancer
@en
P2093
Adolfo Molejon Garcia
Catharina Conrad
Douglas A Lauffenburger
Fred H Rasmussen
Garrit Koller
Jörg W Bartsch
Marcia L Moss
Maud Bossard
Panagiota Golfi
Randal R Ketchem
P2860
P2888
P3181
P356
10.1038/NCOMMS7175
P407
P577
2015-01-28T00:00:00Z
P5875
P6179
1006165357